At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed B-precursor acute lymphoblastic leukemia with standard-risk features meeting specific criteria for SR-average, SR-low, or SR-high
- ✓Initial white blood cell count <50,000/µL
- ✓Age ≥2 years at diagnosis
- ✓Prior enrollment on AALL03B1 required before enrollment on AALL0331
- ✕Overt testicular disease; such patients may be eligible for AALL0232
- ✕Contraindication to additional asparaginase therapy following Induction excludes from SR-Low study
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)
In Brief
A Phase 3 clinical trial evaluating 3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, and 9 other interventions for Acute Lymphoblastic Leukemia and Childhood B Acute Lymphoblastic Leukemia. Completed, enrolled 5,377 participants across 236 sites in 5 countries.
Detailed Summary
This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Study Details
Timeline
Interventions
Some patients undergo cranial radiotherapy
Given IV
Given IV or SC
Given IV or PO
Given IV or IT
Given PO
Given PO
Given IM or IT
Given IM
Given PO
Given IV